DENTAL-MONITORING
24.3.2020 18:50:12 CET | Business Wire | Press release
Dental Monitoring announced last week the launch of a simplified version of SmileMate Virtual Consultation - its tele dentistry solution to allow dental professionals to assess their new patient enquiries remotely and in a HIPAA compliant manner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200324005658/en/
Given the scale of the pandemic, and the increasing containment measures taken by governments worldwide, tele dentistry such as SmileMate Virtual Consultation has emerged as a solution to help assess patients remotely in these unprecedented times - initiating a first consultation from home and preventing the spread of COVID-19.
Standing alongside all dental professionals, Dental Monitoring has now decided to provide until the end of May 2020, free access for SmileMate Virtual Consultation to all individual dentists and orthodontists worldwide.
SmileMate Virtual Consultation is a “light” version of SmileMate, simpler and more immediate to implement for these times - enabling rapid on-boarding and roll-out. It has been developed to allow practices to remotely assess their new patients directly through their website.
CEO and Co-founder of Dental Monitoring, Philippe Salah, explained: “Allowing free access to our solution until the end of May is our duty as global citizens. It is important that we help dental professionals find solutions so they can keep providing their expert care, even during the pandemic .”
On the accelerated development of SmileMate Virtual Consultation, CEO and Founder of SmileMate, Nick Duncan said: “I think I speak for the entire dental industry when I say that our sole focus at this time is to do whatever we can to help clinics get through the current period of uncertainty. We've worked hard to develop a new version of our technology that is easier to implement for both patients and individual clinics. As a partner of dental professionals, making it free for all independent dentists and orthodontists was the right thing to do.”
Dental Monitoring is working with dental professionals, to improve its solutions and help patients access dental care anytime, anywhere.
About SmileMate Virtual Consultation
, remote assessment of new patients.
All new patient calls can be pre-qualified remotely using the SmileMate Virtual Consultation assessment tool directly through the doctor’s practice website. The process is simple:
Step 1 - The doctor simply installs a widget on its practice website. The new patient clicks on the widget, creates a profile and takes five intra-oral pictures on their smartphone (no need to download an App or use a ScanBox and cheek retractors)
Step 2 - A comprehensive customized report is automatically generated by our AI engine and sent to the doctor
Step 3 - The doctor qualifies the patient’s needs on their SmileMate portal
Step 4 - The doctor reviews and personalizes the report before sharing with the patient together with their treatment options and a booking link if an appointment is required.
To implement SmileMate Virtual Consultation, please visit: https://dental-monitoring.com/maintain-patient-care/
After May 31st, 2020, and until the end of the pandemic, SmileMate Virtual Consultation will be available at a reduced 50% cost: US$150/month.
About Fast-Track Accelerated On-Boarding
SmileMate Virtual Consultation is ready for use in minutes after doctors and their teams have performed our free fast-track accelerated onboarding - a new simplified and streamlined implementation process, which is done 100% remotely through webinars and individual support by our customer support team.
To book a time slot for our next training session, please visit: https://dental-monitoring.com/maintain-patient-care/
About Dental Monitoring
(www.dental-monitoring.com
)
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company addressing the dental market. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the dental professionals, and after treatment to ensure the stability of the treatment outcome. The company operates in Europe, the United States and Asia-Pacific. It employs around 250 employees across its five offices located in Paris, Austin, London, Hong Kong and Sydney. SmileMate is a subsidiary of Dental Monitoring (https://www.smilemate.com/
).
View source version on businesswire.com: https://www.businesswire.com/news/home/20200324005658/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Current Chemicals Expands U.S. Production of Rare-Earth Fluorides With New Investment From Momentum Global Ventures5.11.2026 14:14:00 CET | Press release
Current Chemicals receives additional capital to scale U.S. capacity for critical rare-earth fluorides used in magnets, advanced coatings, and alloys Current Chemicals, Inc. (“CCI”), one of the few U.S. companies converting separated rare-earth oxides into the fluorides used to make rare-earth metals and magnets, today announced an additional investment from its lead shareholder, Momentum Global Ventures (“MGV”). The investment will significantly increase CCI’s production of neodymium fluoride, dysprosium fluoride, and other key rare-earth fluorides in Cleveland. The funding adds infrastructure, equipment and engineering staff for fluorides of neodymium, dysprosium, terbium, gadolinium, yttrium, scandium, lanthanum, and lithium for reducing light rare-earths to metal: key inputs for permanent magnets, advanced coatings, and alloys. Neodymium fluoride and dysprosium fluoride are key feedstocks for the metal at the core of high-performance magnets in electric motors, wind turbines and de
iConnections and Preqin, a Part of BlackRock, Announce Collaboration to Bring Institutional Data to Violet, an AI-Powered Capital Introduction Platform5.11.2026 14:00:00 CET | Press release
Preqin's private markets data will be available inside Violet, iConnections' AI-powered capital introduction platform, to help drive networking and greater discovery for attendees of iConnections' Global Alts events iConnections today announced a collaboration with Preqin, a part of BlackRock, that brings one of the industry's leading sources of private markets data and intelligence— spanning fund managers, institutional investors, funds, benchmarks and indices— to Violet, iConnections' AI-powered capital introduction platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105840622/en/ Preqin's data is now inside Violet Powered by Preqin, the integration gives Global Alts attendees access to a broader network of institutional alternatives market participants, inside the same platform where thousands of allocators and managers already discover one another, book meetings and build relationships. “Alternative investing has
SLB OneSubsea Awarded Contract for Lyra Field Development Offshore Norway5.11.2026 13:49:00 CET | Press release
Close collaboration and standardized subsea technology accelerate path to first production Global energy technology company SLB (NYSE: SLB) today announced that its OneSubsea™ joint venture has been awarded a contract by Aker BP to deliver subsea production systems, umbilicals and associated services for the Lyra field development, formerly known as Kjøttkake, on the Norwegian Continental Shelf (NCS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104799196/en/ The SLB (NYSE: SLB) OneSubsea™ joint venture has been awarded a contract by Aker BP to deliver subsea production systems, umbilicals and associated services for the Lyra field development, formerly known as Kjøttkake, on the Norwegian Continental Shelf (NCS). Building on nearly a decade of collaboration through Aker BP’s alliance model, Aker BP and SLB OneSubsea worked together from the early stages of the project to shape the development strategy for Lyra. The fie
EURONAVAL 2026: Naval Group and Technology Innovation Institute (TII) Sign an Agreement to Pool Their Expertise in Advanced Autonomous Underwater Technologies.5.11.2026 12:48:00 CET | Press release
Signed on 3rd November 2026, the agreement brings together TII’s expertise in autonomous systems and Naval Group’s expertise in naval autonomous systems design, development and integration to explore the development and commercialization of advanced autonomous underwater solutions. The Technology Innovation Institute, the applied-research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has signed an agreement with Naval Group, a global leader in naval defense, to advance cooperation in autonomous underwater technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105684133/en/ EURONAVAL 2026: Naval Group and Technology Innovation Institute (TII) sign an agreement to pool their expertise in advanced autonomous underwater technologies. (Photo: AETOSWire) Announced during Euronaval 2026, the collaboration will focus on exploring opportunities for the joint development and commercialization of uncrewed
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates5.11.2026 12:00:00 CET | Press release
Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior yearBRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter, an increase of 34% from the prior yearDiluted GAAP Earnings per American Depository Share (ADS) of $3.28 for the third quarter; non-GAAP diluted Earnings per ADS of $4.59 for the third quarterRaised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billion BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom